AWARD NUMBER: W81XWH-14-1-0428

TITLE: Exploiting Tumor-Activated Testes Proteins To Enhance Efficacy of First-Line Chemotherapeutics in NSCLC

PRINCIPAL INVESTIGATOR: Angelique Whitehurst, PhD

CONTRACTING ORGANIZATION: University of Texas Southwestern Medical Center Dallas, TX 75390-9020

REPORT DATE: October 2016

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

-					Form Approved
R	EPORI DOC	UMENIATIO	N PAGE		OMB No. 0704-0188
Public reporting burden for this data needed, and completing a this burden to Department of D 4302. Respondents should be valid OMB control number. PL	collection of information is estin nd reviewing this collection of in efense, Washington Headquart aware that notwithstanding any EASE DO NOT RETURN YOU	nated to average 1 hour per resp formation. Send comments rega ers Services, Directorate for Infor other provision of law, no persor R FORM TO THE ABOVE ADDR	onse, including the time for revie irding this burden estimate or an mation Operations and Reports is shall be subject to any penalty ESS.	wing instructions, searc y other aspect of this cc (0704-0188), 1215 Jeffe for failing to comply with	hing existing data sources, gathering and maintaining the illection of information, including suggestions for reducing rson Davis Highway, Suite 1204, Arlington, VA 22202- n a collection of information if it does not display a currently
1. REPORT DATE	:	2. REPORT TYPE		3. D	ATES COVERED
October 2016		Annual		30	0 Sep 2015 – 29 Sep 2016
4. TITLE AND SUBTIT	LE			5a.	CONTRACT NUMBER
Exploiting Tumor-Activated Testes Proteins To Enhance Chemotherapeutics in NSCLC			Efficacy of First-Line	ə 5b.	grant number W81XWH-14-1-0428
				5c.	PROGRAM ELEMENT NUMBER
6. AUTHOR(S) Angelique Whitehurst, PhD				5d.	PROJECT NUMBER
5 1	,			5e.	TASK NUMBER
				5f. \	WORK UNIT NUMBER
E-Mail:Angelique.	Vhitehurst@utsout	nwestern.edu			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)				8. P N	ERFORMING ORGANIZATION REPORT
University of Texas	S S dia al Osunta n				
Southwestern M	edical Center				
Dollog TV 75200					
Dallas, 1X 75390-3	9020				
9. SPONSORING / MC	NITORING AGENCY N	AME(S) AND ADDRESS	S(ES)	10.	SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command					
Fort Detrick, Maryl	and 21702-5012			11.	SPONSOR/MONITOR'S REPORT NUMBER(S)
12. DISTRIBUTION / A	VAILABILITY STATEN	IENT			
Approved for Public Release: Distribution Unlimited					
	·				
13. SUPPLEMENTAR	YNOTES				
14. ABSTRACT Cancer Testis Anti ovaries), but freque during spermatoge (DSB) during home environmental insu in NSCLC and are biological and in vi are also essential inactivation of met vivo. The physical damage inducing o	gens (CTAs) are a ently activated in N enesis. Their deleti ologous recombina ilts such as hypoxia essential for tumor vo activity of CTAs to survival of these abolic pathways that interaction network drugs is under invest	group of proteins wh on Small Cell Lung on in mice leads to i tion in meiosis. DSB a and reactive oxyge cell survival. To eva in NSCLC. We have cells in vitro. We fin at lead to the genera of CTAs and identif stigation.	nose expression is r Cancer (NSCLC). A nfertility due to an ir s frequently occur it en species. We hyp aluate this hypothes e identified CTAs th d that the expression tion of DNA-damag ication of additional	restricted to re number of the nability to repa n the tumorige othesize that (sis, we are inve at are essentia on of meiotic C le species. The I CTAs that ma	productive tissues (testis and ese CTAs are essential for meiosis ir DNA Double Strand breaks nic environment due to CTAs promote repair of these DSB estigating the biochemical, cell al for DNA DB in NSCLC and which TAs appears to be a marker for the ese findings are under testing in ay mediate sensitivity to DNA-
Cancer Testis Anti	gen (CTA), Fancor	ia-Anemia (FA), DN	A Damage, Genom	ic Instability, D	DNA Double Strand Break (DSB)
16. SECURITY CLASS	IFICATION OF:		17. LIMITATION	18. NUMBER	19a. NAME OF RESPONSIBLE PERSON
			UT ABUTRACI	UT TAGES	
			Unclassified 9 ^{19D.} IELEPHONE NUMBER (include area		code)
Unclassified	Unclassified	Unclassified			

Table of Contents

Page

4
4
4
7
7
7
8
9
9

1. INTRODUCTION: This proposal is focused on elucidating the function of Cancer-Testes Antigens (CTAs) in Non-Small Cell Lung Cancer. CTAs are genes whose expression is restricted to the testes but frequently reactivated in many tumor types. The purpose of this proposal is to elucidate the contribution of CTAs to the maintenance of genomic integrity at the molecular level and to examine whether CTAs modulate sensitivity to chemotherapy. To do this, a cohort of meiotic CTAs will be examined for their functional contribution to the activation of DNA damage repair pathways. These CTAs, TEX15, HORMAD1 and SYCP1 were implicated as important to NSCLC in preliminary studies. In addition, physical interactions between CTAs and components of the DNA repair machinery will be assessed. In vitro and in vivo studies will be used to assess the contribution of CTAs to tumor cell viability and chemosensitivity. A larger scale analysis of whether additional CTAs contribute to chemotherapeutic sensitivity will also be carried out.

2. Keywords:

- o Cancer Testis Antigen (CTA)
- o Fanconia-Anemia (FA)
- o DNA Damage
- o Genomic Instability
- o DNA Double Strand Break (DSB)

3. Accomplishments

• What were the major goals and objectives of the project?

0-12 months:

- 1) To analyze the FA pathway in CTA-depleted lung cancer cells (Vaziri Lab)
- 2) Complete Lentiviral-mediated CTA overexpression in HBE cells and analyze the FA pathway. (Vaziri Lab)
- 3) Complete dose curve and transfection optimization for a panel of NSCLC cell lines. (Whitehurst Lab)
- 4) Perform sensitivity assays for TEX15, SYCP1 and HORMAD1. (Whitehurst Lab)
- 5) Obtain IACUC approval for in vivo studies. (Whitehurst Lab)
- 6) Develop shRNA stable cell lines. (Whitehurst Lab)
- 7) Initiate in vivo studies. (Whitehurst Lab)

12-24 months:

- 8) Analyze ectopically-expressed epitope-tagged CTA in lung cancer cell lines. (Vaziri Lab)
- 9) Immunopurification and proteomic analysis of CTA complexes in cancer cells. (Vaziri Lab)
- 10)Screen for CTAs contributing to DNA damage. (Whitehurst Lab)

11)Continue in vivo studies. (Whitehurst Lab)

- What was accomplished under these goals? (Since this is a CO-PI grant, the descriptions are split into Aim 1 (Vaziri) and Aim 2 (Whitehurst) for the accomplishment section.
- **AIM 1:** For each major goal proposed in SA1, major activities, specific objectives, and significant results/key outcomes are as follows:

Task: Analysis of ectopically-expressed epitope-tagged CTA in lung cancer cells (1.2). **Major activities:** To express wild-type and mutant CTA in cultured cells and study the dynamic regulation of those CTA in relation to other elements of the DNA damage response.

Specific objectives: To define the proximal DSB-induced events that regulate CTA function following genotoxic injury, and to validate viral expression vectors to be used for proteomic studies.



Structure/function analysis of HORMAD1 - We

generated a panel of HORMAD1 mutants harboring deletions and point mutations in various domains. WT and mutant forms of HORMAD1 were introduced into cultured lung carcinoma cells using adenovirus vectors. Several HORMAD1 mutants did not express (most probably due to protein misfolding and/or instability). Mutant proteins that expressed at levels similar to WT HORMAD1 (some of which are described in **Fig. 1**) are currently being studied for responsiveness to DNA DSB and ability to support Homologous Recombination and radioresistance in cells. It is anticipated that these studies will identify key functional

domains of HORMAD1 and identify mechanisms of responsiveness to DSB as well as the molecular mechanism by which HORMAD1 interfaces with the HR machinery.

Task: Immuno-purification and proteomic analysis of CTA complexes in lung cancer cells (1.2)

Major Activities: We performed unbiased proteomic screens for HORMAD1-assocaited proteins. For those experiments lysates from HA-epitope-tagged HORMAD1-expressing cells (or control cultures not expressing ectopic HORMAD1) were immunoprecipitated with anti-HA antibodies and the resulting immune complexes were analyzed by mass spectrometry.

Specific Goals: To define activators and effectors of HORMAD1 in DSB repair

Significant Results: Initial mass spectrometry experiments revealed enrichment of several structural nuclear proteins (spectrin and actinin) in HA-HORMAD1 immunoprecipitates relative to control pulldowns. However, in independent experiments we were unable to validate specific association of any of these potential binding partners with HORMAD1.

Changes in Approach or Methods: Because our standard experimental approach for defining PIN of DNA repair proteins has not identified specific HORMAD1-binding partners we are repeating IP/mass spec experiments using lower-level HORMAD1 expression and more stringent IP conditions to eliminate non-specific binders. As an additional strategy for



eliminating false positives, we will perform IP/mass spec experiments using some of the inactive mutants identified in our structure/function analyses. The rationale is that for our validation experiments we will focus on interactors that bind to the WT HORMAD1 but not mutant forms of HORMAD1 that are inactive in DSB signaling and HR.

AIM 2: The Whitehurst lab activities have been focused on Aim 2, in which we will assess dependency for survival of NSCLC on CTAs for survival or chemosensitivity of NSCLC in vitro and in vivo.

For each major goal proposed in SA2, major activities, specific objectives, and significant results/key outcomes are as follows:

Task: Screen for CTAs contributing to DNA damage. (Aim 2.3)

Major activities: Screening of CTAs to identify those that may sensitize to DNA damage agents in NSCLC. **Specific Objectives.** To identify CTAs that are essential for mitigating the response to first-line chemotherapeutic agents.

Significant results: Using an siRNA based approach we screened ~105 CTAs but did not observe any significant alterations in sensitivity to Cisplatin (Figure 2). This result could mean that no single CTA is capable of significantly sensitizing cells to carboplatin or that our assay conditions were not sensitive enough to detect changes. Changes in approach or methods: Based on this finding, we reevaluate our analysis on HORMAD1, which we could during the first year of work could support viability in certain settings as well as mediate radioresistance in at least one NSCLC setting. Furthermore, we found that cells that express HORMAD1 are resistant to Piericidin A, which is an electron transport chain disrupter, that leads to leakage of reactive oxygen species and downstream DNA damage. We most recently found that HORMAD1 expression is present in nearly 40 % of NSCLC and these patients have a significantly poorer survival and also have an elevated mutation burden, suggesting chronic DNA damage (Figure 3). We observed <u>no other CTA</u> that exhibited this robust pattern of expression, correlation with survival or mutation burden or chemical sensitivity. Taken together, the siRNA results along

with those for



HORMAD1 is a biomarker for resistance to DNA damage in patient populations and could suggest alternative modes of treatment.

Task: Continue in vivo studies to examine the consequences of CTAs on growth in vivo. (Whitehurst Lab) (Aim 2.2) Major Activities: Implant NSCLC tumors depleted of HORMAD1 and examine the consequences on growth in vivo and sensitivity to DNA damage agents.

Specific Objective: To determine whether CTAs can influence the growth of tumors in vivo.

Significant Results: We used a variety of gain and loss of function approaches to first determine if HORMAD1 is essential for tumorigenesis in vivo. Here, we found that either gain of HORMAD1 in a null background (NSCLC that does not express HORMAD1) or loss of HORMAD1 does not impact tumorigenesis. This finding suggests that HORMAD1 is not required for the transformation event (Figure 4). Thus, we are now evaluating the consequences of HORMAD1 loss or gain on sensitivity to chemotherapeutic agents in vivo. Based on our findings that Homologous Recombination is impacted by HORMAD1 loss in vitro, we are using Cisplatin for these studies. We have developed doses (30-60 mg/kg) that appear to be appropriate for in vivo studies based on published data and our own in vivo analysis. In the next year, we will continue with these studies to determine if HORMAD1 is required for in vivo sensitivity to cisplatin and also if cells that express HORMAD1 are more resistant to cisplatin when grown in vivo. These studies will provide important information on the regulation of HORMAD1 in vivo. **Changes to approach or Methods:** No deviations from the original proposal.

Changes in Approach or Methods: As evident from the description above, there has been no significant change in approach or methods from the agency approved application or plan.



vivo. Left panel: Overexpression of HORMAD1 expression on growth in background did no enhance growth significantly. Right: Loss of HORMAD1 (shHORMAD1) did not significantly reduce tumor growth in vivo). Adherence to original timetable: As expected, have largely completed the analysis proposed in the two years. However, as a few of the experiments not proceed as expected, we have had to alter or delay some approaches. In the No cost extension period we will further performs screens to understand HORMAd1 resistance and complete the vivo studies to analyze chemoresistance of HORMAD1 tumors in vivo.

What opportunities for training and professional development has the project provided?

A post-doctoral fellow at UNC (Yanzhe Gao) performed the studies in support of SA1. His training activities included one-on-one work with

Dr. Vaziri and acquisition of new imaging skills in deconvolution fluorescence microscopy (1.2). At UTSW, Jennifer Macion has been performing studies in support of Aim 2. This allowed her to gain new skills with respect to cell biology and screening analysis.

How were the results disseminated to communities of interest?

Nothing to Report

What do you plan to do during the next reporting period to accomplish the goals?

As described above, we will continue to evaluate the HORMAD1 positive cohort and screen this cohort for radio and chemosensitivity to DNA damage agents and evaluate the requirement for HORMAD1. We will also determine if additional CTAs are essential for the HORMAD1 mediated process. We will further evaluate these findings in vivo during the no cost extension period.

4. Impact

Nothing to report.

- 5. CHANGES/PROBLEMS Nothing to report.
- 6. **PRODUCTS:**

Nothing to report.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort).

Name:	Angelique Whitehurst
Project Role:	PI
Researcher Identifier (e.g. ORCID ID):	N/A
Nearest person month worked:	1
Contribution to Project:	Wrote SA1 of original proposal and supervised experiments in support of SA1
Funding Support:	This award, federal, private and institutional funds.
Name:	Jennifer Macion
Project Role:	Research Technician
Researcher Identifier (e.g. ORCID ID):	N/A
Nearest person month worked:	11
Contribution to Project:	Jennifer Macion worked on the experiments in Aim 2.
Funding Support:	This award, federal and private foundation funds.
Name:	Cyrus Vaziri
Project Role:	PI (at partner site, UNC)
Project Role: Researcher Identifier (e.g. ORCID ID):	PI (at partner site, UNC) N/A
Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked:	PI (at partner site, UNC) N/A 1
Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked: Contribution to Project:	 PI (at partner site, UNC) N/A 1 Wrote SA1 of original proposal and supervised experiments in support of SA1
Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked: Contribution to Project: Funding Support:	PI (at partner site, UNC) N/A 1 Wrote SA1 of original proposal and supervised experiments in support of SA1 NIH awards and partial support from this award
Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked: Contribution to Project: Funding Support:	PI (at partner site, UNC) N/A 1 Wrote SA1 of original proposal and supervised experiments in support of SA1 NIH awards and partial support from this award
Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked: Contribution to Project: Funding Support: Name:	PI (at partner site, UNC) N/A 1 Wrote SA1 of original proposal and supervised experiments in support of SA1 NIH awards and partial support from this award Yanzhe Gao
Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked: Contribution to Project: Funding Support: Name: Project Role:	PI (at partner site, UNC) N/A 1 Wrote SA1 of original proposal and supervised experiments in support of SA1 NIH awards and partial support from this award Yanzhe Gao Post-doc (at partner site, UNC)
Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked: Contribution to Project: Funding Support: Name: Project Role: Researcher Identifier (e.g. ORCID ID):	PI (at partner site, UNC) N/A 1 Wrote SA1 of original proposal and supervised experiments in support of SA1 NIH awards and partial support from this award Vanzhe Gao Post-doc (at partner site, UNC) N/A
Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked: Contribution to Project: Funding Support: Name: Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked:	PI (at partner site, UNC) N/A 1 Wrote SA1 of original proposal and supervised experiments in support of SA1 NIH awards and partial support from this award Yanzhe Gao Post-doc (at partner site, UNC) N/A 11
Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked: Contribution to Project: Funding Support: Name: Project Role: Researcher Identifier (e.g. ORCID ID): Nearest person month worked: Contribution to Project:	PI (at partner site, UNC) N/A 1 Wrote SA1 of original proposal and supervised experiments in support of SA1 NIH awards and partial support from this award Yanzhe Gao Post-doc (at partner site, UNC) N/A 11 Dr. Gao performed all the experiments described under 'work accomplished'

Has there been a change in the active other support of the PD/PIs since the last reporting period? Nothing to Report

What other organizations were involved as partners? University of North Carolina at Chapel Hill Chapel Hill, North Carolina

Partner's Contribution to the project: Collaboration

8. SPECIAL REPORTING REQUIREMENTS: None

9. APPENDICES: (Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.) None